Theranica

Theranica Bio-Electronics was founded in 2016 by Alon Ironi, Ronen Jashek, and Slava Rom. The company is headquartered in Netanya, Israel, with US commercial operations based in New Jersey. Theranica is a privately held digital health and medical device company. Its flagship product is Nerivio, an FDA-cleared, smartphone-controlled wearable device for the acute and preventive treatment of migraine.

Theranica's core product, Nerivio, is a prescribed wearable applied to the upper arm. It utilizes Remote Electrical Neuromodulation (REN) to activate the body's native conditioned pain modulation (CPM) mechanism, offering a non-pharmacological alternative for migraine relief. The device connects to a smartphone app, which allows patients to control the treatment intensity and track their headache diary. It is sold primarily through a prescription model in the US and Israel. The company's technical moat relies on its proprietary REN mechanism, published clinical trial data, and subsequent FDA clearances.

Nerivio operates in the migraine treatment sector, competing with other non-invasive neuromodulation devices such as Cefaly and gammaCore, as well as traditional pharmacological migraine treatments like triptans and CGRP inhibitors. Theranica initially received FDA clearance for the acute treatment of episodic migraine in adults in 2019, and has since expanded its label to include chronic migraine, preventive treatment, and use in adolescents.

The company's R&D, engineering, and global operations are based in Netanya. Key executives, including the founders, operate primarily out of Israel. The local engineering teams focus on hardware development, embedded software, and the accompanying mobile applications required to operate the Nerivio device.